论文部分内容阅读
我国第一个完全拥有自主知识产权的一类抗癌新药参一胶囊将正式进入双盲临床研究阶段。中国中医研究院等全国30多家三级甲等医院将在全国寻找600位癌症患者,投入新药的临床研究。
China’s first completely own independent intellectual property rights of a class of anticancer drugs, a capsule will officially enter the double-blind clinical research stage. China Academy of Traditional Chinese Medicine and other more than 30 tertiary level hospitals throughout the country will look for 600 cancer patients, into new drug clinical research.